STAT3 and gastric cancer: Our data suggested that SDL-1 as a potent STAT3 degrader may be a potential anti-gastric cancer drug candidate, and PROTAC targeting STAT3 may be a new and effective gastric cancer therapeutic strategy (Figure 7B).